Free Trial

Michael Ryskin Analyst Performance

Analyst at Bank of America

Michael Ryskin is a stock analyst at Bank of America in the medical sector, covering 6 publicly traded companies. Over the past year, Michael Ryskin has issued 6 stock ratings, including buy and hold recommendations. While full access to Michael Ryskin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Ryskin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 6 Years
Buy Recommendations
30.00% 3 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy30.0%3 ratings
Hold70.0%7 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Michael Ryskin at Bank of America, the majority (70.0%) have been Hold recommendations, followed by 30.0% Buy.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
3 companies
NASDAQ
50.0% of companies on NASDAQ
3 companies

Michael Ryskin, an analyst at Bank of America, currently covers 6 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Michael Ryskin of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MEDICAL SERVICES
1 company
16.7%
MEDICAL INFO SYS
1 company
16.7%
MED PRODUCTS
1 company
16.7%
MED INSTRUMENTS
1 company
16.7%
MED - DRUGS
1 company
16.7%
MED - OUTP/HM CRE
1 company
16.7%

Michael Ryskin's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Revvity Inc. stock logo
RVTY
Revvity
9/22/2025Lower Price Target$86.36$99.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
6/25/2025Boost Price Target$67.14$70.00Neutral
Tempus AI, Inc. stock logo
TEM
Tempus AI
5/20/2025Boost Price Target$63.74$68.00Neutral
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3/3/2025Lower Price Target$3.22$8.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
3/3/2025Boost Price Target$56.18$60.00Neutral
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2/4/2025Boost Price Target$469.04$535.00Neutral